

B1 --This application is a continuation of PCT/EP99/01996, filed March 24, 1999, which claims the benefit of priority of a German application No. 198 12 941.6, filed March 24, 1998, the contents of each being expressly incorporated herein by reference.--

On page 13 and continuing to page 14, after the last full paragraph on page 13 and before the first full paragraph on page 14, please insert the following paragraph in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

B2 --Fig. 5 shows tumor protection in C57BL16 mice by L1 Δ CE7₁₋₆₀ CVLPs. Two weeks after innoculation of 6×10^4 TC-1 cells, the mice received a single injection of L1 Δ CE7₁₋₆₀ CVLPs. The mice were analyzed for the presence of tumors.--

On page 14, delete the second full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

B3 For the preparation of HPV-16L1 Δ C, two primers were constructed which are complementary to HPV-16L1 ORF. The first primer has the sequence AAAGATATCTTGTAGTAAAAATTTGCGTCCTAAAGGAAAC (SEQ ID NO:1) and the second primer AAAGATATCTAATCTACCTCTACAACCTGCTAAACGCAAAAAACG. (SEQ ID NO:2)

On page 14 and 15, delete the last full paragraph on page 14, continuing on to the first paragraph of page 15, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

B4 For the cloning of the fragment, primers having a 5'EcoRV restriction enzyme cleavage site were used. The following primer pair was used: AAAAGATATCATGCATGGAGATACACCTACATTGC (SEQ ID NO:3) and TTTTGATATCGGCTCTGTCCGGTTCTGCTTGTC. (SEQ ID NO:4)

On page 15, delete the third full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

P1: GTTATGACATACATACATTCTATG (L1) (SEQ ID NO:5)
P2: CCATGCATTCCTGCTTGTAGTAAAAATFTGCGTCC (E7) (SEQ ID NO:6)
P3: CTACAAGCAGGAATGCATGGAGATACACC(E7) (SEQ ID NO:7)
P4: CATCTGAAGCTTAGTAATGGGCTCTGTCCGGTTCTG (E7) (SEQ ID NO:8)

On page 16, delete the first and second full paragraphs, and replace these paragraphs with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

P5: CATCTGAAGCTTATCAATAUGTAATGGGCTCTGTCCG (E7 1-55) (SEQ ID NO:9)
P6:
CATCTGAAGCTTACTTGCAACAAAAGGTTACAATATTGTAATGGGCTCTGTCCG (E7 1-60) (SEQ ID NO:10)
P7:
CATCTGAAGCTTAAAGCGTAGAGTCACACTTGCAACAAAAGGTTACAA TATTGTAATGGGCTCTGTCCG (E7 1-65). (SEQ ID NO:11)

HPV16L1ΔC*E7 1-70 was prepared using the clone HPV16L1ΔC*E7 1-65 and the primers P1 and P8.

P8:
CATCTGAAGCTTATTGTACGCACAACCGAAGCGTAGAGTCACACTTG (SEQ ID NO:12)